Hello Nature readers, would you like to get this Briefing in your inbox free every day? Sign up here.
People with HIV could benefit from semaglutide, the blockbuster drug marketed as Wegovy for obesity and Ozempic for diabetes. If early data about the treatment’s effects are confirmed, semaglutide and other drugs like it could become key to controlling the metabolic problems associated with anti-HIV medications. Studies presented last week at a conference suggest it helps people with HIV to lose weight and reduces certain conditions associated with fat accumulation that are especially common in people infected with the virus.
Nature | 3 min read
Researchers have launched an initiative calling for the safe and ethical use of protein design. The voluntary effort comes on the heels of reports from lawmakers, think tanks and other organizations exploring the possibility that AI tools — ranging from protein-structure prediction networks such as AlphaFold to large language models such as the one that powers ChatGPT — could make it easier to develop biological weapons, including new toxins or highly transmissible viruses. The new initiative calls for the biodesign community to police itself and for improved screening of DNA synthesis, a key step in making AI-designed proteins, for potentially harmful molecules.
Nature | 3 min read
Keep up to date with the latest in the field with Nature Briefing: AI & Robotics — update your preferences to sign up for free.
Features & opinion
In 2020, physicist Ranga Dias claimed to have discovered the first room-temperature superconductor — a material that would not require any cooling to conduct electricity with zero resistance — in a landmark paper published in Nature. It was retracted. Then came a fresh claim in another Nature paper, in 2023 — also later retracted. Now, an investigation by Nature’s news team (which is editorially independent of its journal teams) reveals how Dias distorted the evidence for room-temperature superconductivity — and indicates that he concealed information from his students, manipulated them and shut them out of key steps in the research and review process. The scandal raises questions about how universities, journals and funders deal with research misconduct.
Nature | 22 min read
Reference: Nature paper 1 (retracted) & paper 2 (retracted)
Events such as the resignation of Harvard president Claudine Gay and the suicide of university administrator Antoinette Candia-Bailey came as no surprise to Nicola Rollock, who studies social policy and race. “Black female scholars and staff members continue to face exclusion and challenges in academia that often remain ignored,” writes Rollock. She outlines concrete actions that individual academics and institutions can take to demonstrate solidarity with Black women, including paying fairly, “citing our work and championing us”.
Nature | 4 min read
Researchers who set up a confusing puzzle box with a sweet reward revealed that bumblebees (Bombus terrestris) can learn skills from others that they could not acquire alone — a behaviour thought to be unique to people. After showing that no lone bee could work out how to solve the puzzle, the scientists painstakingly trained nine bees how to do it. The trained bees became demonstrators for other bees, who watched, learnt and won their reward.
Nature | 8 min video
Reference: Nature paper
On Friday, our penguin puzzle took us to the gleaming Ziquejie Rice Terraces in Hunan, China, where Leif Penguinson was hiding. Did you find the penguin? When you’re ready, here’s the answer.
Thanks for reading,
Flora Graham, senior editor, Nature Briefing
With contributions by Smriti Mallapaty and Sarah Tomlin
Want more? Sign up to our other free Nature Briefing newsletters:
• Nature Briefing: Anthropocene — climate change, biodiversity, sustainability and geoengineering
• Nature Briefing: AI & Robotics — 100% written by humans, of course
• Nature Briefing: Cancer — a weekly newsletter written with cancer researchers in mind
• Nature Briefing: Translational Research covers biotechnology, drug discovery and pharma